Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Sold by Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A.

Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. decreased its holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 78.2% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 53,954 shares of the company's stock after selling 193,089 shares during the quarter. Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. owned approximately 0.05% of Neurocrine Biosciences worth $7,365,000 as of its most recent filing with the SEC.

Other institutional investors have also modified their holdings of the company. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in Neurocrine Biosciences by 19.7% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,070,096 shares of the company's stock valued at $146,068,000 after buying an additional 175,879 shares in the last quarter. Worldquant Millennium Advisors LLC raised its stake in Neurocrine Biosciences by 44.1% during the fourth quarter. Worldquant Millennium Advisors LLC now owns 154,852 shares of the company's stock valued at $21,137,000 after buying an additional 47,370 shares in the last quarter. Triglav Skladi D.O.O. acquired a new stake in Neurocrine Biosciences during the fourth quarter valued at approximately $1,502,000. Teza Capital Management LLC raised its stake in Neurocrine Biosciences by 4.5% during the fourth quarter. Teza Capital Management LLC now owns 17,864 shares of the company's stock valued at $2,438,000 after buying an additional 765 shares in the last quarter. Finally, Strategic Global Advisors LLC raised its stake in Neurocrine Biosciences by 4.2% during the fourth quarter. Strategic Global Advisors LLC now owns 20,521 shares of the company's stock valued at $2,801,000 after buying an additional 827 shares in the last quarter. Institutional investors and hedge funds own 92.59% of the company's stock.

Insider Buying and Selling at Neurocrine Biosciences

In other news, Director William H. Rastetter sold 30,000 shares of the business's stock in a transaction on Monday, May 5th. The shares were sold at an average price of $110.20, for a total transaction of $3,306,000.00. Following the transaction, the director now directly owns 37,491 shares in the company, valued at $4,131,508.20. The trade was a 44.45% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Company insiders own 4.80% of the company's stock.

Neurocrine Biosciences Stock Up 1.5%

NBIX opened at $122.82 on Tuesday. The firm has a market capitalization of $12.16 billion, a P/E ratio of 37.33, a PEG ratio of 0.77 and a beta of 0.26. The stock has a fifty day moving average of $107.30 and a 200-day moving average of $121.93. Neurocrine Biosciences, Inc. has a 12-month low of $84.23 and a 12-month high of $157.98.

Neurocrine Biosciences (NASDAQ:NBIX - Get Free Report) last released its earnings results on Monday, May 5th. The company reported $0.08 earnings per share for the quarter, missing the consensus estimate of $0.70 by ($0.62). Neurocrine Biosciences had a net margin of 14.49% and a return on equity of 13.38%. The business had revenue of $572.60 million for the quarter, compared to analysts' expectations of $587.06 million. During the same period last year, the firm earned $1.20 EPS. The company's revenue was up 11.1% compared to the same quarter last year. On average, analysts expect that Neurocrine Biosciences, Inc. will post 4.28 earnings per share for the current fiscal year.

Neurocrine Biosciences declared that its board has authorized a share buyback program on Friday, February 21st that authorizes the company to repurchase $500.00 million in outstanding shares. This repurchase authorization authorizes the company to purchase up to 4.2% of its shares through open market purchases. Shares repurchase programs are typically a sign that the company's management believes its stock is undervalued.

Analyst Ratings Changes

NBIX has been the topic of several research reports. Canaccord Genuity Group upped their price objective on Neurocrine Biosciences from $158.00 to $160.00 and gave the company a "buy" rating in a research note on Tuesday, May 6th. UBS Group increased their price target on Neurocrine Biosciences from $137.00 to $152.00 and gave the stock a "buy" rating in a research report on Tuesday, May 6th. Wedbush reiterated an "outperform" rating on shares of Neurocrine Biosciences in a research report on Tuesday, May 6th. BMO Capital Markets increased their price objective on Neurocrine Biosciences from $96.00 to $115.00 and gave the stock a "market perform" rating in a report on Tuesday, May 6th. Finally, Bank of America decreased their price objective on Neurocrine Biosciences from $184.00 to $179.00 and set a "buy" rating for the company in a report on Friday, February 7th. Three equities research analysts have rated the stock with a hold rating and twenty have given a buy rating to the stock. Based on data from MarketBeat, Neurocrine Biosciences presently has a consensus rating of "Moderate Buy" and a consensus price target of $162.00.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.